Akero Therapeutics, Inc.
AKRO
|
$20.76
1.22%
1.2%
790K
|
Health Technology
(0.0% 1d) (-20.0% 1m) (-55.2% 1y) (1.2% 2d) (1.2% 3d) (-4.4% 7d) (3.73% volume)
Earnings Calendar: 2024-03-15
Market Cap: $ 1,435,574,905
http://www.akerotx.com
Sec Filling | Patents | 13 employees
(United States) Akero Therapeutics, Inc. operates as a biotechnology company. The firm specializes in transformational treatments for non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases. The company was founded by Jonathan Young and Timothy Rolph on January 24, 2017 and is headquartered in South San Francisco, CA.
metabolic efruxifermin liver disease liver nash msa treatment
add to watch list Paper trade email alert is off
Press-releases
Ademi LLP Investigates Claims of Securities Fraud against Akero Therapeutics, Inc.
Published: 2024-04-02 (Crawled : 22:00) - prnewswire.com
PIK | $3.59 -4.78% -5.01% 94K
|
|
| O: -7.63%
H: 8.26%
C: 2.61%
MORF | $28.0 1.78% 1.75% 380K
|
Health Technology
|
| O: -1.16%
H: 1.78%
C: 0.57%
AKRO | $20.76 1.22% 1.2% 790K
|
Health Technology
|
| O: -0.73%
H: 1.16%
C: -0.13%
Akero Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
Published: 2024-03-08 (Crawled : 21:00) - globenewswire.com
AKRO | $20.76 1.22% 1.2% 790K
|
Health Technology
| Email alert
Add to watchlist
MS | News 0 d | $90.66 0.44% 0.07% 8.1M
|
Finance
| Email alert
Add to watchlist
offering therapeutics
Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and Hepatology
Published: 2024-03-07 (Crawled : 21:00) - globenewswire.com
AKRO | $20.76 1.22% 1.2% 790K
|
Health Technology
|
| O: 0.16%
H: 5.27%
C: 0.81%
publication therapeutics study
Akero Therapeutics Announces Pricing of Public Offering of Common Stock
Published: 2024-03-06 (Crawled : 03:00) - globenewswire.com
MS | News 0 d | $90.66 0.44% 0.07% 8.1M
|
Finance
|
| O: -2.65%
H: 1.36%
C: -1.28%
AKRO | $20.76 1.22% 1.2% 790K
|
Health Technology
|
| O: 2.23%
H: 3.85%
C: -3.85%
offering therapeutics
Akero Therapeutics Announces Pricing of Public Offering of Common Stock - March 06, 2024
Published: 2024-03-06 (Crawled : 12:00) - biospace.com/
MS | News 0 d | $90.66 0.44% 0.07% 8.1M
|
Finance
|
| O: -2.65%
H: 1.36%
C: -1.28%
AKRO | $20.76 1.22% 1.2% 790K
|
Health Technology
|
| O: 2.23%
H: 3.85%
C: -3.85%
offering therapeutics
Akero Therapeutics Announces Proposed Public Offering of Common Stock
Published: 2024-03-04 (Crawled : 21:00) - globenewswire.com
MS | News 0 d | $90.66 0.44% 0.07% 8.1M
|
Finance
|
| O: -0.94%
H: 2.19%
C: -0.07%
AKRO | $20.76 1.22% 1.2% 790K
|
Health Technology
|
| O: -1.03%
H: 1.95%
C: -0.75%
offering therapeutics
Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study
Published: 2024-03-04 (Crawled : 11:00) - globenewswire.com
AKRO | $20.76 1.22% 1.2% 790K
|
Health Technology
|
| O: 27.68%
H: 4.2%
C: -12.5%
week therapeutics study
Akero Therapeutics to Present Topline Week 96 Results from Phase 2b HARMONY Study Investigating Efruxifermin in Patients with Pre-Cirrhotic MASH
Published: 2024-02-29 (Crawled : 13:00) - globenewswire.com
AKRO | $20.76 1.22% 1.2% 790K
|
Health Technology
|
| O: 2.94%
H: 6.28%
C: -3.71%
efruxifermin topline week therapeutics results study
Akero Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Published: 2024-02-29 (Crawled : 12:00) - globenewswire.com
AKRO | $20.76 1.22% 1.2% 790K
|
Health Technology
|
| O: 2.94%
H: 6.28%
C: -3.71%
business year update therapeutics financial results
Akero Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Published: 2024-01-03 (Crawled : 13:00) - globenewswire.com
AKRO | $20.76 1.22% 1.2% 790K
|
Health Technology
|
| O: -0.72%
H: 0.0%
C: -4.72%
conference therapeutics
Last 15 days Sec forms
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 67% | 33% |
Top 10 Gainers
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
NYC 4 | $5.91 -4.83% 14.38% 770
|
Finance
GBR | $1.42 31.48% 11.27% 990K
|
Energy Minerals
DEO | News | $140.76 -0.02% 8.27% 560K
|
Consumer Non-Durables
KUKE | $2.88 2.49% 7.64% 360K
|
MGLD 4 | $1.23 8.85% 7.32% 14K
|
Manufacturing
GRFX | $0.2116 -1.58% 7.28% 40K
|
n/a
LYT | $4.22 4.72% 5.62% 1.4M
|
SYY | $76.73 1.44% 5.49% 2.5M
|
Distribution Services
TWI | $11.53 0.96% 4.94% 330K
|
Producer Manufacturing
Last 48 Hours Insiders Buying
RXO P 200000 | $19.37 2.32% 0.0% 1M
|
n/a
|
23:00
RKT P 380 | $11.68 1.3% 0.17% 1.9M
|
Finance
|
22:30
HROW P 29400 | $10.43 -3.87% -4.03% 680K
|
Health Technology
|
22:30
BCDA P 2750 | $0.377 -1.4% 97K
|
Health Technology
|
22:00
RMCF | $3.67 3.38% 3.27% 11K
|
Consumer Non-Durables
|
20:10